Methyl P-Toluenesulfonyl-L-Argininate

Methyl P-Toluenesulfonyl-L-Argininate

SCHEMBL324561

COC(=O)[C@H](CCCNC(=N)N)NS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.57
ITGA2B P08514 2/20 0.57
PLAU P00749 7/20 0.52
HPN P05981 7/20 0.52
BMP1 P13497 3/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
MAPT P10636 1/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
ADAM10 O14672 1/20 0.43
MMP12 P39900 1/20 0.43
MMP14 P50281 1/20 0.43
ADAM8 P78325 1/20 0.43
ADAM17 P78536 1/20 0.43
LMNA P02545 1/20 0.43
ALB P02768 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl P-Toluenesulfonyl-L-Argininate SCHEMBL2853451 1.00 ITGB3 (0.57) ITGB3ITGA2BPLAUHPNBMP1
Methyl P-Toluenesulfonyl-L-Argininate SCHEMBL1034821 0.99 ITGB3 (0.56) ITGB3ITGA2BPLAUHPNBMP1
Methyl P-Toluenesulfonyl-L-Argininate SCHEMBL11880215 0.99 ITGB3 (0.56) ITGB3ITGA2BPLAUHPNBMP1
SCHEMBL1839480 0.92 ITGB3 (0.56) ITGB3ITGA2BPLAUHPNALDH1A1
SCHEMBL1839478 0.92 ITGB3 (0.56) ITGB3ITGA2BPLAUHPNALDH1A1
Methoxymethane SCHEMBL8925022 0.90 ITGB3 (0.67) ITGB3ITGA2BPLAUHPNMMP2
SCHEMBL27734963 0.90 BMP1 (0.52) ITGB3ITGA2BBMP1MMP2MMP9
SCHEMBL1244355 0.90 ITGB3 (0.60) ITGB3ITGA2BPLAUHPNALDH1A1
SCHEMBL17318886 0.89 ITGB3 (0.54) ITGB3ITGA2BPLAUHPNALDH1A1
Hydrochloric Acid SCHEMBL7319933 0.88 ITGB3 (0.59) ITGB3ITGA2BPLAUHPNALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720329-A1 REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD SensID GmbH (DE) 2026-04-08 EP claimed
WO-2024246014-A1 REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD SENSID GMBH (DE) 2024-12-05 WO claimed
EP-4467659-A1 REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS WITH A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSIS SensID GmbH (DE) 2024-11-27 EP claimed
US-20020187520-A1 ALLERGEN/ INFLAMMATORY TESTING AND DIAGNOSIS HELM BIRGIT ANNA (GB) 2002-12-12 US claimed
US-6177268-B1 DISSOLVING TRYPSIN IN BUFFER SOLUTION HAVING PH AT WHICH TRYPSIN IS ACTIVE, PKA IS HIGHER THAN PH OF BUFFER, AND SOLUTION HAS CALCIUM AND MANGANESE IONS; STORAGE STABILITY ARKRAY, INC. (JP) 2001-01-23 US claimed
EP-0671004-A1 ALLERGEN/INFLAMMATORY TESTING AND DIAGNOSIS EURO/DPC LIMITED (GB) 1995-09-13 EP claimed
WO-1994012876-A1 ALLERGEN/INFLAMMATORY TESTING AND DIAGNOSIS EURO/DPC LIMITED (GB) 1994-06-09 WO claimed
JP-57016698-A None JP disclosed
JP-3004790-A None JP disclosed
EP-4720329-A1 REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD SensID GmbH (DE) 2026-04-08 EP disclosed
US-12559544-B2 Antibodies that bind human metapneumovirus fusion protein and their use UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2026-02-24 US disclosed
EP-4686765-A1 METHOD FOR PROGNOSIS OF BLADDER CANCER Istituto Europeo di Oncologia S.r.l. (IT) 2026-02-04 EP disclosed
US-20260007705-A1 PROBIOTIC COMPOSITIONS FOR PRODUCTION OF DOPAMINE UNIV IOWA STATE RES FOUND INC (US) 2026-01-08 US disclosed
US-4224342-A ANTI-PLASMIN AND ANTI-TRYPSIN ACTIVITY ONO PHARMACEUTICAL CO., LTD. (JP) 1980-09-23 US disclosed
US-4214093-A PROTEOLYTIC ENZYME INHIBITORS TORII & CO., LTD. (JP) 1980-07-22 US disclosed
EP-0008746-A1 Alpha-(N-arylsulfonyl-L-argininamides, processes for their preparation and pharmaceutical compositions containing these substances MITSUBISHI KASEI CORPORATION (JP) 1980-03-19 EP disclosed
US-4182897-A ENZYME INHIBITORS FOR PROTEOLYTIC ENZYMES TORII & CO., LTD. (JP) 1980-01-08 US disclosed
US-4118575-A Derivatives of para-guanidino-L-phenylalanine and methods of preparing them CHOAY S.A. (FR) 1978-10-03 US disclosed
US-4075405-A CYANOGEN HALIDE TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1978-02-21 US disclosed
US-3954678-A Semipermeable microcapsules containing a silica gel E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559544-B2 Antibodies that bind human metapneumovirus fusion protein and their use FCGR3B, FCGR2A, FCGR1A ITGB3 2695/4885ITGA2B 3033/4885PLAU 3428/4885
US-20260007705-A1 PROBIOTIC COMPOSITIONS FOR PRODUCTION OF DOPAMINE PRLHR, SLC6A2, TPH2 ITGB3 4243/4885ITGA2B 4097/4885PLAU 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.